NCT02555735
Exceptional Responders With Solid Tumor Cancer to Chemotherapy
Enrolling by Invitation
Not specifiedAges 18+ObservationalAdera Labs, LLC
~250 participants
Updated 2023-02-01 on ClinicalTrials.gov
What's tested:Standard of Care Chemotherapy
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Identify exceptional responders with cancer to standard of care chemotherapy
Measured over 9 years
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Brian McCarthy, PhD · STUDY_DIRECTOR · Adera Labs
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histological or cytological confirmation of solid tumor carcinoma.
Patient is treatment-naïve or currently receiving chemotherapy.
ECOG performance status (any).
Exclusion
HIV positive on antiretroviral therapy
Pregnant or lactating
Prior organ allograft
Any medical or psychiatric condition that may interfere with the ability to comply with protocol treatment
What this trial measures
- Identify exceptional responders with cancer to standard of care chemotherapy9 years
Identify responders and non-responders